Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7678MR)

This product GTTS-WQ7678MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in B-cell malignancies research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Chimeric
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7678MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15475MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-0107
GTTS-WQ10762MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ7126MR IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FE 999302
GTTS-WQ8980MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ5548MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP7657
GTTS-WQ4514MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ8226MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ10333MR IVTScrip™ mRNA-Anti-IL17A&TNFSF13B, LY 3090106(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY 3090106
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW